1. Articles in category: Diagnosis and Detection

    1-24 of 67 1 2 3 »
    1. Prospective investigation of applicability and the prognostic significance of bone marrow involvement in patients with neuroblastoma detected by quantitative reverse transcription PCR.

      Prospective investigation of applicability and the prognostic significance of bone marrow involvement in patients with neuroblastoma detected by quantitative reverse transcription PCR.

      Pediatr Blood Cancer. 2018 Jul 14;:e27354

      Authors: Druy AE, Shorikov EV, Tsaur GA, Popov AM, Zaychikov AN, Tuponogov SN, Saveliev LI, Tytgat GAM, Fechina LG

      Read Full Article
      Mentions: Bone Marrow PHOX2B
    2. Prospective investigation of applicability and the prognostic significance of bone marrow involvement in patients with neuroblastoma detected by quantitative reverse transcription PCR

      Expression of PHOX2B , TH , ELAVL4 , and B4GALNT1 (GD2‐synthase) was analyzed by quantitative polymerase chain reaction in neuroblastoma cell lines, control BM samples, and in BM samples from patients. The threshold level of expression for each gene was established through receiver operator characteristic analysis and used to determine the diagnostic test performance. The prognostic significance of BM involvement was assessed by survival rates calculations.

      Read Full Article
      Mentions: Bone Marrow PHOX2B
    3. Olive ingestion causing a false suspicion of relapsed neuroblastoma: A case of "oliveblastoma?"

      Olive ingestion causing a false suspicion of relapsed neuroblastoma: A case of "oliveblastoma?"

      Pediatr Blood Cancer. 2018 Jun 19;:e27248

      Authors: Flynn N, LeFebvre A, Messahel B, Hogg SL

      Abstract Measurement of the urine catecholamine metabolites homovanillic acid (HVA) and vanillylmandelic acid (VMA) are the standard method for detecting disease recurrence in neuroblastoma.

      Read Full Article
    4. Suppression of RRM2 inhibits cell proliferation, causes cell cycle arrest and promotes the apoptosis of human neuroblastoma cells and in human neuroblastoma RRM2 is suppressed following chemotherapy.

      Suppression of RRM2 inhibits cell proliferation, causes cell cycle arrest and promotes the apoptosis of human neuroblastoma cells and in human neuroblastoma RRM2 is suppressed following chemotherapy.

      Oncol Rep. 2018 May 08;:

      Authors: Li J, Pang J, Liu Y, Zhang J, Zhang C, Shen G, Song L

      Read Full Article
      Mentions: Chemotherapy
    5. Usefulness of fluorodeoxyglucose positron emission tomography/computed tomography for detection of a neuroblastic nodule in a ganglioneuroblastoma: a case report.

      Usefulness of fluorodeoxyglucose positron emission tomography/computed tomography for detection of a neuroblastic nodule in a ganglioneuroblastoma: a case report.

      J Med Case Rep. 2018 May 03;12(1):119

      Authors: Takeda Y, Sano H, Kawano A, Mochizuki K, Takahashi N, Kobayashi S, Ohara Y, Tasaki K, Hosoya M, Kikuta A

      Read Full Article
      Mentions: MYCN
    6. Diagnostic performance of 18F-FDG PET/CT and whole-body diffusion-weighted imaging with background body suppression (DWIBS) in detection of lymph node and bone metastases from pediatric neuroblastoma.

      Diagnostic performance of 18F-FDG PET/CT and whole-body diffusion-weighted imaging with background body suppression (DWIBS) in detection of lymph node and bone metastases from pediatric neuroblastoma.

      Ann Nucl Med. 2018 Apr 17;:

      Authors: Ishiguchi H, Ito S, Kato K, Sakurai Y, Kawai H, Fujita N, Abe S, Narita A, Nishio N, Muramatsu H, Takahashi Y, Naganawa S

      Read Full Article
      Mentions: Imaging MIBG
    7. Prenatally detected thoracic neuroblastoma.

      Prenatally detected thoracic neuroblastoma.

      Obstet Gynecol Sci. 2018 Mar;61(2):278-281

      Authors: Park Y, Lee HJ, Jung YJ, Lee JH, Kwon JY, Kim YH

      Abstract Neuroblastoma is the most common pediatric extracranial solid tumor derived from primitive neural crest cells of the sympathetic nervous system. Although one-fifths of all neuroblastomas occurs within the thorax, thoracic neuroblastomas detected in fetus have been rarely reported.

      Read Full Article
    8. The absence of a novel intron 19-retaining ALK transcript (ALK-I19) and MYCN amplification correlates with an excellent clinical outcome in neuroblastoma patients.

      The absence of a novel intron 19-retaining ALK transcript (ALK-I19) and MYCN amplification correlates with an excellent clinical outcome in neuroblastoma patients.

      Oncotarget. 2018 Feb 13;9(12):10698-10713

      Authors: Alshareef A, Irwin MS, Gupta N, Zhang HF, Haque M, Findlay SD, Seong BKA, Lai J, Rayis M, Al-Dandan S, Lai R

      Read Full Article
      Mentions: ALK MYCN
    9. The Presence of ALK Alterations and Clinical Relevance of Crizotinib Treatment in Pediatric Solid Tumors.

      The Presence of ALK Alterations and Clinical Relevance of Crizotinib Treatment in Pediatric Solid Tumors.

      Pathol Oncol Res. 2017 Oct 28;:

      Authors: Felkai L, Bánusz R, Kovalszky I, Sápi Z, Garami M, Papp G, Karászi K, Varga E, Csóka M

      Abstract Soft tissue sarcomas (STS) and neuroblastomas (NBL), are childhood malignancies still associated with poor prognoses despite the overall improvement in childhood tumor survival of the past decades.

      Read Full Article
      Mentions: Treatment ALK
    10. RT-qPCR for PHOX2B mRNA is a highly specific and sensitive method to assess neuroblastoma minimal residual disease in testicular tissue.

      RT-qPCR for PHOX2B mRNA is a highly specific and sensitive method to assess neuroblastoma minimal residual disease in testicular tissue.

      Oncol Lett. 2017 Jul;14(1):860-866

      Authors: Grèze V, Kanold J, Chambon F, Halle P, Gremeau AS, Rives N, Rouel N, Pereira B, Tchirkov A, Brugnon F

      Read Full Article
      Mentions: PHOX2B
    11. New biomarker assay detects neuroblastoma with greater sensitivity

      Investigators have developed and tested a new biomarker assay for quantifying disease and detecting the presence of neuroblastoma even when standard evaluations yield negative results for the disease. Researchers provide the first systematic comparison of standard imaging evaluations versus the new assay that screens for five different neuroblastoma-associated genes and determine that the new assay improves disease assessment and provides prediction of disease progression.

      Read Full Article
      Mentions: NANT Imaging MIBG
    12. New biomarker assay detects neuroblastoma with greater sensitivity

      New biomarker assay detects neuroblastoma with greater sensitivity

      ( Children's Hospital Los Angeles ) Investigators at The Saban Research Institute of Children's Hospital Los Angeles have developed and tested a new biomarker assay for quantifying disease and detecting the presence of neuroblastoma even when standard evaluations yield negative results for the disease.

      Read Full Article
      Mentions: NANT MIBG
    13. Unusual Presentation of Relapse in Neuroblastoma: Pancreatic Metastases Detected by 123I-MIBG Scintigraphy.

      "Neuroblastoma is the most common extracranial solid tumor in children and accounts for 8% to 10% of all childhood cancers. The spread of metastases is both lymphatic and hematogenous. Hematogenous route occurs most commonly in bone marrow and cortical bone; pancreatic metastases are very rare, and there are few reports about this topic in medical literature. We report the case of a 14-year-old boy who suffers a third relapse of neuroblastoma: in this patient I-MIBG confirms that lesions detected by CT were due to a relapse in pancreatic tissue and influenced subsequent therapeutic management."

      Read Full Article
      Mentions: Relapse MIBG
    14. An Evidence-based Recommendation for a Standardized Approach to Detecting Metastatic Neuroblastoma in Staging Bone Marrow Biopsies.

      An Evidence-based Recommendation for a Standardized Approach to Detecting Metastatic Neuroblastoma in Staging Bone Marrow Biopsies.

      Pediatr Dev Pathol. 2017 Jan-Feb;20(1):38-43

      Authors: Parsons LN, Gheorghe G, Yan K, Simpson P, Jarzembowski JA

      Abstract Neuroblastoma is a common malignant tumor of childhood. Accurate bone marrow (BM) evaluation for metastatic tumor is essential; however, no standardized pathologic workup exists for staging BMs.

      Read Full Article
      Mentions: Staging Bone Marrow
    15. New assay shows promise to advance personalized therapy for cancer patients

      New assay shows promise to advance personalized therapy for cancer patients

      ( Elsevier Health Sciences ) The National Cancer Institute's NCI-MATCH (Molecular Analysis for Therapy Choice) is a large, ongoing clinical trial that matches tumors to therapies based on the tumor's genetic characteristics. A report in The Journal of Molecular Diagnostics confirms that the assay tailored for this trial is highly sensitive for detecting genetic mutations from a variety of tumor tissue and, for the first time, has been reproduced with accuracy by multiple clinical laboratories, laying the groundwork for future clinical utility.

      Read Full Article
      Mentions: Diagnostics
    16. Neuroblastoma: A spectrum of cells isolated from bone marrow of patients.

      "Flow cytometry can detect neuroblastoma cells as low as 0.001% within the heparinized samples and used to characterize the cultured cells. Cell culture showed a spectrum of neuronal morphology. Neurospheres express lower levels of GD2, TrkB, and CD56 compared to adherent neuroblastoma (consistent results were obtained using flow cytometry, immunofluoresence, immunohistochemistry, and mRNA expression analysis). Tumorigenicity was confirmed using mice injected subcutaneously with patient neurospheres tumors were present at the injection site and metastasized. Bone marrow aspirates of patients with neuroblastoma can be analyzed for the presence of neuroblastoma initiating cells which can be further characterized. This may play ...

      Read Full Article
      Mentions: Bone Marrow
    17. Patterns of Diagnosis and Misdiagnosis in Pediatric Cancer and Relationship to Survival.

      "The median time from symptom onset to diagnosis was shortest for leukemia (18.5 d) and longest for bone tumors (86.5 d). Tumor type was the only factor associated with time to diagnosis. In 52% of cases an incorrect nononcological diagnosis was initially made. Soft tissue sarcomas and brain tumors were misdiagnosed most often. Neither prolonged time to diagnosis nor initial misdiagnosis was associated with reduced survival. Tumor type and presence of metastatic disease at diagnosis were significantly associated with survival."

      Read Full Article
    18. Early detection of tumor relapse/regrowth by consecutive minimal residual disease monitoring in high-risk neuroblastoma patients.

      "The present study reports two high-risk neuroblastoma patients, whose MRD was consecutively monitored using 11 RT-qPCR markers (CHRNA3, CRMP1, DBH, DCX, DDC, GABRB3, GAP43, ISL1, KIF1A, PHOX2B and TH) during their course of treatment. The two patients initially responded to the induction therapy and reached MRD-negative status. The patients' MRD subsequently became positive with no elevation of their urinary homovanillic acid, urinary vanillylmandelic acid and serum neuron-specific enolase levels at 13 or 19 weeks prior to the clinical diagnosis of tumor relapse or regrowth. The present cases highlight the possibility of consecutive MRD monitoring using 11 markers to enable an ...

      Read Full Article
      Mentions: Relapse PHOX2B
    19. Differential expression of minimal residual disease markers in peripheral blood and bone marrow samples from high-risk neuroblastoma patients.

      Differential expression of minimal residual disease markers in peripheral blood and bone marrow samples from high-risk neuroblastoma patients.

      Oncol Lett. 2015 Nov;10(5):3228-3232

      Authors: Yamamoto N, Kozaki A, Hartomo TB, Yanai T, Hasegawa D, Kawasaki K, Kosaka Y, Matsuo M, Hirase S, Mori T, Hayakawa A, Iijima K, Nishio H, Nishimura N

      Read Full Article
      Mentions: Bone Marrow PHOX2B
    20. Novel pharmacodynamic biomarkers for MYCN protein and PI3K/AKT/mTOR pathway signaling in children with neuroblastoma.

      "We have addressed the issue of limited access to tumor biopsies for quantitative detection of protein biomarkers by optimizing a three-color fluorescence activated cell sorting (FACS) method to purify CD45-/GD2+/CD56+ neuroblastoma cells from bone marrow. We then developed a novel quantitative measurement of MYCN protein in these isolated neuroblastoma cells, providing the potential to demonstrate proof of concept for drugs that inhibit PI3K/AKT/mTOR signaling in this disease. In addition we have established quantitative detection of three biomarkers for AKT pathway activity (phosphorylated and total AKT, GSK3β and P70S6K) in surrogate platelet-rich plasma (PRP) from pediatric patients ...

      Read Full Article
      Mentions: MYCN
    21. The Sooner the Better? How Symptom Interval Correlates With Outcome in Children and Adolescents With Solid Tumors: Regression Tree Analysis of the Findings of a Prospective Study

      "Our analysis suggests that at least a subset of patients can benefit from an earlier diagnosis in terms of survival. For others, intrinsic aggressiveness may mask the potential effect of diagnostic delays. Based on these findings, early diagnosis should remain a goal for pediatric cancer patients."

      Read Full Article
    1-24 of 67 1 2 3 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles

  3. Researches in the News

    1. (2 articles) Bone Marrow
    2. (2 articles) PHOX2B